Human Papillomavirus (HPV) Prophylaxis Landscape, 2017

November 2017 | 79 pages | ID: H13F3DFE775EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Human PapillomaVirus (HPV) Prophylaxis Landscape, 2017’ Report provides an overview of the Human PapillomaVirus (HPV) and market trends of the Human PapillomaVirus (HPV) Vaccines in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and Rest of World (RoW).

The Report also provides in-depth analysis on the HPV Vaccines covering pre-clinical and clinical studies and Collaborations details. The Report provides the HPV vaccines licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. The Report provides a comprehensive review of the market trends, key company profiles including its business and product developments.

The HPV vaccines have been introduced in US and most EU/EEA countries. As of May 2012, the vaccination advisory bodies in 22 of 29 countries has made a recommendation in favor of HPV vaccination, compared to 12 out of 27 countries in February 2008 in Europe. According to DelveInsight, a total of 7,288,315 people were vaccinated with HPV Vaccines in 2016 and the total number of vaccinated people with HPV Vaccine is expected to reach XXXX in 2025.

According to DelveInsight, the Total Market Size of Human PapillomaVirus (HPV) Vaccines including 6MM (the United States and EU5 countries) and RoW was estimated to be USD 1.98 Billion in 2016. The market is expected to reach a total of USD XXXX Millions by 2025 with a CAGR OF XXX% for the period 2015-2025. Market size has increased in recent years for HPV due to the approval of Gardasil 9 (Merck & Co.) which targets 9 different HPV types (Types 16, 18, 31, 33, 45, 52, and 58). Although the overall HPV Vaccines market is increasing, the sales of Cervarix (GlaxoSmithKline) has been declining over the years owing to the company’s decision to stop the vaccines’ supply in the United States. GlaxoSmithKline has taken this step due to the low market demand of Cervarix in the US.

KEY COVERAGE AND BENEFITS:

• The report will help in developing business strategies by understanding the trends shaping and driving the global Human PapillomaVirus (HPV) Vaccines market.
• Organize sales and marketing efforts by identifying the best opportunities for Human PapillomaVirus (HPV) Vaccines in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
• To understand the future market competition in the global Human PapillomaVirus (HPV) Vaccines market and Insightful review of the key market drivers and barriers.
• To understand the regulatory scenario in major markets.
• Overview of the global HPV Vaccines pipeline scenario, products and associated companies information.
• Coverage of global HPV Vaccines under development.
• Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.
• The Report also covers the detailed global historical and forecasted Human PapillomaVirus (HPV) Vaccines market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.

Contents

Report Introduction
Executive Summary
Human PapillomaVirus (HPV) Vaccines Market Overview at a Glance
7 MM and ROW Market Size of Human PapillomaVirus (HPV) Vaccines (2015-2025)
Total Market Share Distribution of Human PapillomaVirus (HPV) Vaccines for 7 MM in 2016
Total Market Share Distribution of Human PapillomaVirus (HPV) Vaccines for 7 MM in 2025
Human papillomavirus (HPV)
Categories of Human papillomavirus (HPV)
Causes
Cancers caused by HPV
The HPV vaccination
Mechanism of Action of HPV Vaccines
Summary of HPV vaccine characteristics
HPV Infection and Cervical Cancer
Epidemiology and Patient Population
United States
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in United States
Europe
Germany
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in Germany
France
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in France
United Kingdom
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in United Kingdom
Spain
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in Spain
Italy
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in Italy
Japan
Population with Human PapillomaVirus (HPV) Vaccination (2015-2025) in Japan
HPV Prophylaxis
Mid Stage Products (Phase II)
Comparative Analysis
INO-3112: Inovio Pharmaceuticals, Inc.
Product Description
Research and Development
Product Development Activities
INO-3112
Early Stage Products (Phase I)
Comparative Analysis
CKD-12201: Chong Kun Dang Pharmaceutical Corp.
Product Description
Product Development Activities
EG-HPV: EyeGene, Inc.
Product Description
Research and Development
Product Development Activities
EG-HPV
Pre-clinical Products
Comparative Analysis
iBiomodulator with the E7GGG or E7 antigens: iBio Inc.
Product Description
Research and Development
Product Development Activities
AX03: Agilvax
Product Description
Research and Development
Product Development Activities
AX03
HPV Vaccine: Soligenix
Product Description
Research and Development
HPV Vaccine
Marketed Vaccines
Cervarix: GlaxoSmithKline
Gardasil/ Gardasil 9: Merck & Co., Inc.
Gardasil Story
Pipeline Scenario
HPV Vaccine Key Players
Global Human PapillomaVirus (HPV) Vaccines: Country-Wise Market Analysis
Region-Specific Market Distribution and Comparison
Overview on Total Human PapillomaVirus (HPV) Vaccines Market (2016)
Overview on Total Human PapillomaVirus (HPV) Vaccines Market (2025)
Global Human PapillomaVirus (HPV) Vaccines: Market Analysis
United States Market Size
Europe
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Rest of World (RoW) Scenario
Unmet Needs
SWOT Analysis
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List Of Tables

LIST OF TABLES

Table 1: 6 Major Market and ROW Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million (2015-2025)
Table 2: Summary of HPV vaccine characteristics
Table 3: Population with Human PapillomaVirus (HPV) Vaccination in United States(2015-2025)
Table 4: Population with Human PapillomaVirus (HPV) Vaccination in Germany (2015-2025)
Table 5: Population with Human PapillomaVirus (HPV) Vaccination in France (2015-2025)
Table 6: Population with Human PapillomaVirus (HPV) Vaccination in United Kingdom (2015-2025)
Table 7: Population with Human PapillomaVirus (HPV) Vaccination in Spain (2015-2025)
Table 8: Population with Human PapillomaVirus (HPV) Vaccination in Italy (2015-2025)
Table 9: Population with Human PapillomaVirus (HPV) Vaccination in Japan(2015-2025)
Table 10: Gardasil/Gardasil 9 Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Table 11: Region specific market distribution and comparison
Table 12: Total Human PapillomaVirus (HPV) Vaccines Market Size (2016) - 6MM
Table 13: Total Human PapillomaVirus (HPV) Vaccines,Market Size(2025) as per the 6MM
Table 14: United States Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Table 15: Germany Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Table 16: France Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Table 17: United Kingdom Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million,(2015-2025)
Table 18: Spain Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Table 19: Italy Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Table 20: ROW Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)

List Of Figures

LIST OF FIGURES

Figure 1: Three-Dimensional Model of Human PapillomaVirus (HPV)
Figure 2: Programmatic interventions to prevent HPV infections and cervical cancer
Figure 3:Population with Human PapillomaVirus (HPV) Vaccination in United States(2015-2025)
Figure 4: Population with Human PapillomaVirus (HPV) Vaccination in Germany (2015-2025)
Figure 5: Population with Human PapillomaVirus (HPV) Vaccination in France (2015-2025)
Figure 6: Population with Human PapillomaVirus (HPV) Vaccination in United Kingdom(2015-2025)
Figure 7: Population with Human PapillomaVirus (HPV) Vaccination in Spain (2015-2025)
Figure 8: Population with Human PapillomaVirus (HPV) Vaccination in Italy (2015-2025)
Figure 9: Population with Human PapillomaVirus (HPV) Vaccination in Japan (2015-2025)
Figure 10: Gardasil/Gardasil 9 Vaccines in USD Million, (2015-2025)
Figure 11: Region-specific market distribution and comparison
Figure 12: Total 6 Major Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2016)
Figure 13: Total 6 Major Market Size of Human PapillomaVirus (HPV) Vaccines in USD Millions, (2025)
Figure 14: United States Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Figure 15: Germany Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Figure 16: France Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Figure 17: United Kingdom Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Figure 18: Spain Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Figure 19: Italy Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)
Figure 20: ROW Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2015-2025)